SCHEMBL20178682

SCHEMBL20178682

O=C(O)c1ccc2c(c1)CCN(S)C2

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
HDAC6 Q9UBN7 6/20 0.46
HDAC8 Q9BY41 1/20 0.46
MYC P01106 1/20 0.44
AKR1C3 P42330 7/20 0.44
AKR1C1 Q04828 3/20 0.43
SRD5A2 P31213 3/20 0.42
SRD5A1 P18405 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.42
BLM P54132 1/20 0.42
GRM1 Q13255 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20178664 0.81 HDAC6 (0.51) HDAC6HDAC8SRD5A2SRD5A1MAPK1
SCHEMBL17560164 0.81 NOTUM (0.61) ALDH1A1HDAC6HDAC8MYCAKR1C3
SCHEMBL30839551 0.80 ALDH1A1 (0.61) ALDH1A1HDAC6HDAC8MYCAKR1C3
SCHEMBL3313430 0.80 ALDH1A1 (0.61) ALDH1A1HDAC6HDAC8MYCAKR1C3
Hydrochloric Acid SCHEMBL3313566 0.79 ALDH1A1 (0.59) ALDH1A1HDAC6HDAC8MYCAKR1C3
SCHEMBL3440252 0.77 ALDH1A1 (0.67) ALDH1A1HDAC6MYCSRD5A2SRD5A1
SCHEMBL28052395 0.77 MYC (0.56) ALDH1A1HDAC6HDAC8MYCAKR1C3
SCHEMBL20173793 0.76 ALDH1A1 (0.51) ALDH1A1HDAC6HDAC8MYCAKR1C3
SCHEMBL7788367 0.76 ITGB3 (0.58) ALDH1A1AKR1C3AKR1C1KDM4EPOLB
SCHEMBL17869203 0.76 ALDH1A1 (0.51) ALDH1A1HDAC6AKR1C3AKR1C1SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 ALDH1A1 2185/4885HDAC6 597/4885HDAC8 1166/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 ALDH1A1 2185/4885HDAC6 597/4885HDAC8 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.